ATLANTA, April 4 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. today announced that the company will be presenting at BIO 2006 Business Forum which is being held as part of BIO 2006, the Biotechnology Industry Organization's Annual International Convention being held at McCormick Place Convention Center in Chicago, Illinois from April 9-12, 2006. Michael K. Steele, Vice President-Business Development for Corautus Genetics, will be giving the company's corporate presentation on Tuesday, April 11th, at 11:45 a.m. in Room B, McCormick Place South, Level 3 Exhibit Hall A.
The Bio Business Forum is the largest partnering and networking program in the industry. It is a program that offers pharmaceutical companies, biotechnology companies, academic research institutions and investors from around the world the unique opportunity to gather in one place at one time to learn about each other and to meet one-on-one to discuss business opportunities of mutual interest.
About Corautus Genetics
Corautus Genetics Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative gene therapy products for the treatment of cardiovascular (severe angina) and peripheral vascular disease. Corautus is focusing its efforts and resources on the development of gene therapy products using a growth factor known as Vascular Endothelial Growth Factor-2, or VEGF-2, gene to promote therapeutic angiogenesis in ischemic muscle. Corautus has a strategic alliance with Boston Scientific Corporation to develop, commercialize and distribute the VEGF-2 gene therapy products. For more information, please visit www.corautus.com.
Forward-Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our ongoing clinical trial, including its costs, potential benefits from manufacturing agreements, the potential benefits from previous clinical trials, sufficient and timely enrollment of suitable patients in our clinical trial, future results of operations or our financial condition, recommencement of our GENASIS trial, adequacy of funding, benefits from the alliance with Boston Scientific, research, development and commercialization of our product candidates, anticipated trends in our business, manufacture of sufficient and acceptable quantities of our proposed products, approval of our product candidates, meeting additional capital requirements, and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' 2005 Annual Report on Form 10-K which was filed on March 20, 2006, which are incorporated by reference into this press release.
For more information, please visit http://www.corautus.com . Company Contact: Michael K. Steele Vice President - Business Development (404) 526-6212 msteele@corautus.com Investor Relations Contacts: Lippert/Heilshorn & Assoc Kim Sutton Golodetz Kgolodetz@lhai.com Anne Marie Fields afields@lhai.com 212-838-3777
Corautus Genetics Inc.CONTACT: Michael K. Steele, Vice President-Business Development ofCorautus Genetics Inc., +1-404-526-6212, or msteele@corautus.com; orInvestor Relations, Kim Sutton Golodetz, Kgolodetz@lhai.com, or Anne MarieFields, afields@lhai.com, or +1-212-838-3777, of Lippert-Heilshorn & Assoc.
Web site: http://www.corautus.com/
